Drug Safety

, Volume 14, Issue 5, pp 329–342 | Cite as

Bodyweight Change as an Adverse Effect of Drug Treatment

Mechanisms and Management
  • Hanno Pijl
  • A. Edo Meinders
Review Article Drug Experience


A number of drugs are capable of changing bodyweight as an adverse effect of their therapeutic action. Bodyweight gain is more of a problem than bodyweight loss. As bodyweight gain during drug treatment for any kind of disease may be the reflection of improvement of the disease itself, we will try to separate these effects from those due to drug-induced alterations of the mechanisms regulating bodyweight. Bodyweight gain may jeopardise patient compliance to the prescribed regimen and it may pose health risks.

The body mass index (BMI) is determined by dividing bodyweight in kilograms by height in metres squared. A BMI of ≥27 kg/m2 warrants therapeutic action; nutritional counselling and programmed physical exercise can be used as a basis. In general, if basic therapeutic measures are unsuccessful at controlling bodyweight gain then a change of drug might help. Finally, an anoretic drug may serve to support dietary measures. However, safety and efficacy has been demonstrated for only a few anorectic drugs when used as an adjunct to caloric restriction in the treatment of drug-induced obesity.

Bodyweight is determined by complex mechanisms regulating energy balance. A number of neurotransmitter systems acting in several hypothalamic nuclei are pivotal to the regulation of body fat stores. Most drugs that are capable of changing bodyweight interfere with these neurotransmitter systems. The increment is dependent on the type and dose of the drug concerned.

Some antidepressant drugs induce bodyweight gain, which may amount to 20kg over several months of treatment. Monoamine oxidase inhibitors appear to cause less bodyweight change than tricyclic antidepressants. Selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors cause bodyweight loss instead of bodyweight gain. Lithium may cause large increases in bodyweight. Generally speaking, the bodyweight change induced by antipsychotics is more often of clinical significance than the bodyweight change associated with the use of antidepressants. Again, the changes of bodyweight are dependent upon the type and dose of the antipsychotic drug involved. Although almost all antipsychotics induce bodyweight gain, molindone and loxapine appear to induce bodyweight loss. Anticonvulsants, especially valproic acid (sodium valproate) and carbamazepine, induce bodyweight gain in a considerable percentage of patients.

Treatment with corticosteroids is associated with dose-dependent bodyweight gain in many patients. Corticosteroid-induced obesity aggravates other cortico-steroid-associated health risks. Insulin therapy in diabetic patients usually increases bodyweight. Finally, sulphonurea derivatives, antineoplastic agents used for the treatment of breast cancer and several drugs used in migraine prophylaxis may cause bodyweight gain as well.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forbes JM. Metabolic aspects of the regulation of voluntary food intake and appetite. Nutr Res Rev 1988; 1: 145–68PubMedCrossRefGoogle Scholar
  2. 2.
    Morley JE. An approach to the development of drugs for appetite disorders. Neuropsychobiology 1989; 21: 22–30PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz MS, Figlewicz DP, Baskin DG, et al. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992; 13: 387–414PubMedGoogle Scholar
  4. 4.
    Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546–95PubMedCrossRefGoogle Scholar
  5. 5.
    Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992; 15: 491–7PubMedCrossRefGoogle Scholar
  6. 6.
    Pijl H, Meinders AE. Brain serotonin and food selection: history and current perceptions. J Serot Res 1994; 1: 21–45Google Scholar
  7. 7.
    Leibowitz SF, Weiss GF, Shor Posner G. Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 1988; 11Suppl. 1: s51–S71PubMedGoogle Scholar
  8. 8.
    Leibowitz SF, Weiss GF, Walsh UA, et al. Medial hypothalamic serotonin: role in circadian patterns of feeding and macronutrient selection. Brain Res 1989; 503: 132–40PubMedCrossRefGoogle Scholar
  9. 9.
    Goldman CK, Marino L, Leibowitz SF. Postsynaptic α2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and Clonidine. Eur J Pharmacol 1985; 115: 11–91PubMedCrossRefGoogle Scholar
  10. 10.
    Leibowitz SF. Catecholaminergic mechanisms of the lateral hypothalamus: their role in the mediation of amphetamine anorexia. Brain Res 1975; 98: 529–45PubMedCrossRefGoogle Scholar
  11. 11.
    Zarrindast MR, Owji AA, Hosseini Nia T. Evaluation of dopamine receptor involvement in rat feeding behaviour. Gen Pharmacol 1991; 22: 1011–6PubMedCrossRefGoogle Scholar
  12. 12.
    Angel I. Central receptors and recognition sites mediating the effects of monoamines and anorectic drugs on feeding behavior. Clin Neuropharmacol 1990; 13: 361–91PubMedCrossRefGoogle Scholar
  13. 13.
    Jansky L. Humoral thermogenesis and its role in maintaining energy balance. Physiol Rev 1995; 75: 237–59PubMedGoogle Scholar
  14. 14.
    Pi-Sunyer FX. Medical Hazards of Obesity. Ann Intern Med 1993; 119: 655–60PubMedGoogle Scholar
  15. 15.
    Bray GA, Gray DS. Treatment of obesity: an overview. Diabetes Metab Rev 1988; 4: 653–79PubMedCrossRefGoogle Scholar
  16. 16.
    Arenillas L. Amitriptyline and body weight. Lancet 1964; I: 432–31CrossRefGoogle Scholar
  17. 17.
    Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973; 123: 501–7PubMedCrossRefGoogle Scholar
  18. 18.
    Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979; 41: 535–44PubMedGoogle Scholar
  19. 19.
    Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133–8PubMedCrossRefGoogle Scholar
  20. 20.
    Fernstrom MH, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Res 1986; 17: 269–73PubMedCrossRefGoogle Scholar
  21. 21.
    Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987; 48: 27–8PubMedGoogle Scholar
  22. 22.
    Orzack MH, Cole JO, Friedman L, et al. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology 1986; 15: 28–30CrossRefGoogle Scholar
  23. 23.
    Gottfries CG. Influence of depression and antidepressants on weight. Acta Psychiatr Scand 1981; 290: 353–6CrossRefGoogle Scholar
  24. 24.
    Harris B, Young J, Hughes B. Appetite and weight change in patients presenting with depressive illness. J Affect Disord 1984; 6: 331–9PubMedCrossRefGoogle Scholar
  25. 25.
    Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium [review]. J Clin Psychopharmacol 1988; 8: 323–30PubMedCrossRefGoogle Scholar
  26. 26.
    Szarek BL, Brandt DM. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients. J Nerv Ment Dis 1993; 181: 702–4PubMedCrossRefGoogle Scholar
  27. 27.
    Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management [review]. Clin Neuropharmacol 1988; 11Suppl. 1: s194–206PubMedGoogle Scholar
  28. 28.
    Paradis CF, Stack JA, George CJ, et al. Nortriptyline and weight change in depressed patients over 60. J Clin Psychopharmacol 1992; 12: 246–50PubMedCrossRefGoogle Scholar
  29. 29.
    Fernstrom MH, Krowinski RL, Kupfer DJ. Appetite and food preference in depression: effects of imipramine treatment. Biol Psychiatry 1987; 22: 529–39PubMedCrossRefGoogle Scholar
  30. 30.
    Robinson DS, Corcella J, Feighner JP, et al. A comparison of trazodone, amoxapine and maprotiline in the treatment of endogenous depression: results of a multicenter study. Curr Ther Res 1984; 35: 549–60Google Scholar
  31. 31.
    Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs [review]. Int Clin Psychopharmacol 1995; 9Suppl. 5: 21–7PubMedCrossRefGoogle Scholar
  32. 32.
    Kessel JB, Simpson GM. Tricyclic and tetracyclic drugs. In: Kaplan HIS, Adock BJ, editors. Comprehensive textbook of psychiatry/VI. Baltimore: Williams and Wilkins, 1995: 2096–112Google Scholar
  33. 33.
    Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994; 30: 193–207PubMedCrossRefGoogle Scholar
  34. 34.
    Fernstrom MH. Depression, antidepressants, and body weight change [discussion]. Ann N Y Acad Sci 1989; 575: 31–9PubMedCrossRefGoogle Scholar
  35. 35.
    Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology 1992; 106 Suppl: s98–101PubMedCrossRefGoogle Scholar
  36. 36.
    Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part 1. A comparative study. J Clin Psychopharmacol 1984; 4: 270–8PubMedCrossRefGoogle Scholar
  37. 37.
    Rabkin J, Quitkin FM, McGrath P, et al. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5: 2–9PubMedCrossRefGoogle Scholar
  38. 38.
    Gander DR. Treatment of depressive illness with combined antidepressants. Lancet 1965; II: 107CrossRefGoogle Scholar
  39. 39.
    Winston F, McCann ML. Antidepressant drugs and excessive weight gain. Br J Psychiatry 1972; 120: 693–4PubMedCrossRefGoogle Scholar
  40. 40.
    Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995; 61: 1020–5PubMedGoogle Scholar
  41. 41.
    Rothwell NJ, Stock MJ. Effect of diet and fenfluramine on thermogenesis in the rat: possible involvement of serotonergic mechanisms. Int J Obes 1987; 11: 319–24PubMedGoogle Scholar
  42. 42.
    Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull 1988; 24: 220–3PubMedGoogle Scholar
  43. 43.
    Harris B, Ashford J. Maintenance antidepressants and weight gain: a comparison of fluvoxamine and amitriptyline. Br J Clin Res 1991; 2: 81–8Google Scholar
  44. 44.
    Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988; 26: 265–71PubMedCrossRefGoogle Scholar
  45. 45.
    Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993; 342: 1419PubMedCrossRefGoogle Scholar
  46. 46.
    Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53(1): 84–8PubMedCrossRefGoogle Scholar
  47. 47.
    Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149: 689–90PubMedGoogle Scholar
  48. 48.
    Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine [see comments]. Am J Psychiatry 1990; 147: 503–4PubMedGoogle Scholar
  49. 49.
    Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–53PubMedCrossRefGoogle Scholar
  50. 50.
    Povlsen UJ, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176–85CrossRefGoogle Scholar
  51. 51.
    Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68–72PubMedGoogle Scholar
  52. 52.
    Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55: suppl B: 157–60PubMedGoogle Scholar
  53. 53.
    Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11: 182–9PubMedGoogle Scholar
  54. 54.
    Gordon HL, Groth C. Weight change during and after hospital treatment. Arch Gen Psychiatry 1964; 10: 187–91PubMedCrossRefGoogle Scholar
  55. 55.
    Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40: 528–30PubMedGoogle Scholar
  56. 56.
    Klett CJ, Caffey EM. Weight changes during treatment with phenothiazine derivates. J Neuropsychiatry 1960; 2: 102–8Google Scholar
  57. 57.
    Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214–7PubMedCrossRefGoogle Scholar
  58. 58.
    Gardos G, Cole JO. Weight reduction in schizofrenics by molindone. Am J Psychiatry 1977; 134: 302–4PubMedGoogle Scholar
  59. 59.
    Kellner R, Rada RT, Egelman A, et al. Long term study of molindone hydrochloride in chronic schizophrenics. Curr Ther Res 1976; 20: 686–93PubMedGoogle Scholar
  60. 60.
    Pickar D. Prospects for pharmacotherapy of schizophrenia [review]. Lancet 1995; 345: 557–62PubMedCrossRefGoogle Scholar
  61. 61.
    Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–86PubMedGoogle Scholar
  62. 62.
    Parada MA, Hernandez L, Hoebel BG. Sulpride injection in the lateral hypothalamus induces feeding and drinking in rats. Pharmacol Biochem Behav 1988; 30: 917–23PubMedCrossRefGoogle Scholar
  63. 63.
    Singh MM, DeDios LV, Kline NS. Weight as a correlate of clinical response to psychotropic drugs. Psychosomatics 1970; 9: 562–70Google Scholar
  64. 64.
    Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59–68PubMedCrossRefGoogle Scholar
  65. 65.
    Roth BL, Craigo SC, Choudhary MS. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 and 5-hydroxytryptamine 7 receptors. J Pharmacol Exp Ther 1994; 268: 1403–10PubMedGoogle Scholar
  66. 66.
    Meitzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18–S27CrossRefGoogle Scholar
  67. 67.
    Weidley EF, Setler PE, Rush JA. The serotonin blocking properties of antipsychotic drugs. Pharmacologist 1980; 22: 279Google Scholar
  68. 68.
    Mc Tavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992; 43: 713–33CrossRefGoogle Scholar
  69. 69.
    Goodall E, Oxtoby C, Richards R, et al. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153: 208–13PubMedCrossRefGoogle Scholar
  70. 70.
    Price LH, Heninger GR. Lithium in the treatment of mood disorders [see comments]. N Engl J Med 1994; 331: 591–8PubMedCrossRefGoogle Scholar
  71. 71.
    Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990; 5: 217–25PubMedCrossRefGoogle Scholar
  72. 72.
    Kerry RJ, Liebling LI, Owen G. Weight changes in lithium responded. Acta Psychiatr Scand 1970; 46: 238–43PubMedCrossRefGoogle Scholar
  73. 73.
    Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139–47PubMedCrossRefGoogle Scholar
  74. 74.
    Peselow ED, Dunner DL, Fieve RR, et al. Lithium carbonate and weight gain. J Affect Disord 1980; 2: 303–10PubMedCrossRefGoogle Scholar
  75. 75.
    Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. Part III. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434–41PubMedCrossRefGoogle Scholar
  76. 76.
    Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. Acta Psychiatr Scand 1980; 62: 193–200PubMedCrossRefGoogle Scholar
  77. 77.
    Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain [review]. Pharmacopsychiatry 1995; 28: 35–44PubMedCrossRefGoogle Scholar
  78. 78.
    Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987; 7: 91–5PubMedCrossRefGoogle Scholar
  79. 79.
    Waldmeier PC. Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry 1987; 20: 37–47PubMedCrossRefGoogle Scholar
  80. 80.
    Dinesen H, Gram L, Veje A. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65–9PubMedCrossRefGoogle Scholar
  81. 81.
    Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283: 557–81Google Scholar
  82. 82.
    Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 436–62Google Scholar
  83. 83.
    Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666–70PubMedCrossRefGoogle Scholar
  84. 84.
    Aston MG, Ball SG, Thomas LH, et al. Water intoxication associated with carbamazepine treatment. BMJ 1977; 1: 1134–5CrossRefGoogle Scholar
  85. 85.
    Kimura T, Matsui K, Sato T, et al. Mechanism of carbamazepine (Tegretol) induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab 1974; 38: 356–62PubMedCrossRefGoogle Scholar
  86. 86.
    Meinders AE, Cejka V, Robertson GL. The antidiuretic action of carbamazepine in man. Clin Sci Mol Med 1974; 47: 289–99PubMedGoogle Scholar
  87. 87.
    Lampl Y, Eshel Y, Rapaport A, et al. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991; 14: 251–5PubMedCrossRefGoogle Scholar
  88. 88.
    Naruse T. Effects of repeated intravenous administration of diazepam on food intake in rats. Fundam Clin Pharmacol 1994; 8: 379–84PubMedCrossRefGoogle Scholar
  89. 89.
    Pang S, Clark AT, Freeman LC, et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 75: 249–53PubMedCrossRefGoogle Scholar
  90. 90.
    Merritt RJ, Hack SL, Kalsch M, et al. Corticosteroid therapy-induced obesity in children. Clin Pediatr 1986; 25: 149–52CrossRefGoogle Scholar
  91. 91.
    Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy [see comments]. Lancet 1993; 342: 949–54PubMedCrossRefGoogle Scholar
  92. 92.
    Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr 1988; 27: 387–92CrossRefGoogle Scholar
  93. 93.
    Curtis JJ, Galla JH, Woodford SY, et al. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981; 1: 166–71PubMedGoogle Scholar
  94. 94.
    Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. Part II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662–6PubMedCrossRefGoogle Scholar
  95. 95.
    Keteyian SJ, Marks CR, Fedel FJ, et al. Assessment of body composition in heart transplant patients. Med Sci Sports Exerc 1992; 24: 247–52PubMedGoogle Scholar
  96. 96.
    Horber FF, Zurcher RM, Herren H, et al. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986; 43: 758–69PubMedGoogle Scholar
  97. 97.
    Hauner H, Bognar E, Blum A. Body fat distribution and its association with metabolic and hormonal risk factors in women with angiographically assessed coronary artery disease. Evidence for the presence of a metabolic syndrome. Atherosclerosis 1994; 105: 209–16PubMedCrossRefGoogle Scholar
  98. 98.
    Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? [review]. Postgrad Med J 1994; 70: 863–70PubMedCrossRefGoogle Scholar
  99. 99.
    Tempel DL, Leibowitz SF. Adrenal steroid receptors: interactions with brain neuropeptide systems in relation to nutrient intake and metabolism [review]. J Neuroendocrinol 1994; 6: 479–501PubMedCrossRefGoogle Scholar
  100. 100.
    Loprinzi CL, Ellison NM, Goldberg RM, et al. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Sem Oncol 1990; 17: 8–12Google Scholar
  101. 101.
    World Health Organization. The WHO multicenter trial of the vasopressor effects of combined oral contraceptives. Part I. Comparison with IUD. Contraception 1989; 40: 129–45CrossRefGoogle Scholar
  102. 102.
    World Health Organisation. The WHO multicenter trial of the vasopressor effects of combined oral contraceptives. Part II. Lack of effect of estrogen. Contraception 1989; 40: 147–56CrossRefGoogle Scholar
  103. 103.
    Manconi FM, Zuddas A, Piccardi MP, et al. Behavioural and biochemical effects of flunarizine on the dopaminergic system in rodents. Cephalalgia 1987; 7: 420–1Google Scholar
  104. 104.
    Smith MA, Youngkin EQ. Current perspectives on combination oral contraceptives [review]. Clin Pharm 1984; 3: 485–96PubMedGoogle Scholar
  105. 105.
    Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21PubMedCrossRefGoogle Scholar
  106. 106.
    PEPI Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208CrossRefGoogle Scholar
  107. 107.
    Renier M, Buytaert P. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene. Contraception 1991; 43: 413–21PubMedCrossRefGoogle Scholar
  108. 108.
    Weber-Diehl F, Lehnert J, Lachnit U. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial. Contraception 1993; 48: 291–301PubMedCrossRefGoogle Scholar
  109. 109.
    O’Sullivan AJ, Hoffman DM, Ho KK. Estrogen, lipid oxidation, and body fat [letter]. N Engl J Med 1995; 333: 669–70PubMedCrossRefGoogle Scholar
  110. 110.
    Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279–82PubMedCrossRefGoogle Scholar
  111. 111.
    Alexieva-Figusch J, Van Gilse HA, Hop WC, et al. Progestin therapy in advanced breast cancer: megestrol acetate — an evaluation of 160 treated cases. Cancer 1980; 46: 2369–72PubMedCrossRefGoogle Scholar
  112. 112.
    Aisner J, Parnes H, Tait N, et al. Appetite stimulation and weight gain with megestrol acetate. Semin Oncol 1990; 17Suppl. 9: 2–7PubMedGoogle Scholar
  113. 113.
    Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus [see comments]. N Engl J Med 1992; 327: 1426–33PubMedCrossRefGoogle Scholar
  114. 114.
    Hickey ME, Hall TR. Insulin therapy and weight change in Native-American NIDDM patients. Diabetes Care 1993; 16: 364–8PubMedCrossRefGoogle Scholar
  115. 115.
    The Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 1993; 11: 567–73Google Scholar
  116. 116.
    Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993; 42: 1700–7PubMedCrossRefGoogle Scholar
  117. 117.
    Hermann LS, Scherstén B, Bitzén P-O, et al. Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 1994; 17: 1100–9PubMedCrossRefGoogle Scholar
  118. 118.
    Hermann LS, Karlsson J-E, Sjöstrand Å. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 1991; 41: 263–5PubMedCrossRefGoogle Scholar
  119. 119.
    Josephcutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabetic Med 1990; 7: 510–4CrossRefGoogle Scholar
  120. 120.
    Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994; 21: 394–400Google Scholar
  121. 121.
    Groop L, Widén E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 599–605PubMedCrossRefGoogle Scholar
  122. 122.
    McAlpine LG, McAlpine CH, Waclawski ER, et al. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. Eur J Clin Pharmacol 1988; 34: 129–32PubMedCrossRefGoogle Scholar
  123. 123.
    Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab 1991; 17: 209–12PubMedGoogle Scholar
  124. 124.
    Leslie P, Jung RT, Isles TE, et al. Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy. Clin Sci 1987; 73: 41–5PubMedGoogle Scholar
  125. 125.
    Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer [review]. J Clin Oncol 1993; 11: 1418–29PubMedGoogle Scholar
  126. 126.
    Goodwin PA, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer — a descriptive study. Breast Cancer Res Treat 1988; 11: 59–66PubMedCrossRefGoogle Scholar
  127. 127.
    Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer-effect of tamoxifen. Breast Cancer Res Treat 1992; 22: 129–32PubMedCrossRefGoogle Scholar
  128. 128.
    Centonze V, Magrone D, Vino M, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia 1990; 10: 17–24PubMedCrossRefGoogle Scholar
  129. 129.
    Meyboom RHB, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986; II: 282Google Scholar
  130. 130.
    Baldrati A, Albano F, de Carolis P, et al. Essential tremor and flunarizine: description of a case. Cephalalgia 1987; 7: 285PubMedCrossRefGoogle Scholar
  131. 131.
    Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. Headache 1986; 26: 83–5PubMedCrossRefGoogle Scholar
  132. 132.
    Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double blind investigation. Cephalalgia 1985; 5: 17–23PubMedCrossRefGoogle Scholar
  133. 133.
    Martinez-Mir I, Navarro-Badenes J, Palop V, et al. Weight gain induced by long-term propranolol treatment [letter]. Ann Pharmacother 1993; 27: 512PubMedGoogle Scholar
  134. 134.
    Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300: 902–3PubMedCrossRefGoogle Scholar
  135. 135.
    Landsberg L, Young JB. Sympathoadrenal activity and obesity — physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes 1993; 17: S29–S34Google Scholar
  136. 136.
    Lonnqvist F, Thorne A, Nillsell K, et al. A pathogenetic role of visceral fat beta-3-adrenoreceptors in obesity. J Clin Invest 1995; 95: 1109–16PubMedCrossRefGoogle Scholar
  137. 137.
    Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients [see comments]. Ann R Coll Surg Engl 1990; 72: 296–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Hanno Pijl
    • 1
  • A. Edo Meinders
    • 1
  1. 1.Department of General Internal MedicineLeiden University HospitalLeidenThe Netherlands

Personalised recommendations